XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
  Muscular Dystrophies
  Pagets Disease
  Falls
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM

Pagets Disease Channel
subscribe to Pagets Disease newsletter

Latest Research : Musculoskeletal : Pagets Disease

   DISCUSS   |   EMAIL   |   PRINT
Studies confirm new treatments for Paget's disease
Sep 5, 2005 - 11:56:00 PM, Reviewed by: Dr.

"The new treatment quickly gives sufferers a much improved quality of life, and has a much lower rate of relapse than the conventional treatment."

 
Two studies led by researchers at The University of Auckland's Faculty of Medical and Health Sciences have pioneered new, more effective treatment for two forms of Paget's disease - a chronic and often painful bone disease.

The results of the studies, one led by Professor Ian Reid, who heads the University's Bone Research Group, and the other by his colleague, Professor Tim Cundy have been published in separate articles in the latest edition of the prestigious New England Journal of Medicine.

Professor Reid led an international study which confirmed a new treatment for Paget's disease, giving a more rapid, effective and longer-lasting result than existing medication.

Professor Cundy's research focused on Juvenile Paget's disease, a rare genetic bone disease with some similarities to adult Paget's. Having earlier been involved in the identification of the genetic cause of the disease, he used an experimental new treatment that substantially relieved bone pain, improved bone density and reversed the metabolic abnormalities of the disease in two patients.

Paget's disease is the second most prevalent bone disease after osteoporosis and affects up to five percent of the older population in New Zealand. It is caused by a malfunction of the body's regular bone building process and results in bone pain, skeletal deformity, bone fractures, deafness and neurological complications. Generally onset is in people over the age of 40.

Juvenile Paget's disease, although very rare is very debilitating. It usually presents in infancy or childhood and results in progressive deformity, growth retardation and deafness.

"Paget's is very painful, affects mobility and can greatly affect the quality of life for sufferers, which is why new treatments are so worthwhile," Professor Reid says.

Professor Reid's international study pioneered the use of zoledronic acid, and showed that a single injection gave a rapid and long-lasting improvement in bone health.

"The new treatment quickly gives sufferers a much improved quality of life, and has a much lower rate of relapse than the conventional treatment."

A further benefit is that it is much easier on the patients - the conventional treatment with tablets requires patients to take daily oral medication in a strict daily regimen for up to six months.

The study involved nearly 360 patients from 10 countries around the world, including 15 from New Zealand.

Based on the results of the study, the new drug under the brand name, Aclasta, was licensed for treatment of Paget's disease in the European Union in April this year, Canada in June and is currently under regulatory review in the United States.

It has not yet been made available in New Zealand for Paget's disease.

Professor Cundy's patients were a brother and sister, who had been wheel-chair bound with Juvenile Paget's since they were 15. He used an experimental new treatment giving them recombinant osteoprotergerin, the protein that is lacking in sufferers and deficiency of which causes the condition.

"While the disease in these patients was too advanced for any treatment to correct deformity, it made enough of an improvement in their bones, and reduction in bone pain for us to believe it could be very useful in halting progress of the disease in infants and children."
 

- New England Journal of Medicine
 

The University of Auckland

 
Subscribe to Pagets Disease Newsletter
E-mail Address:

 



Related Pagets Disease News

Single Infusion of Zoledronic Acid More Effective in Paget�s Disease
Studies confirm new treatments for Paget's disease
European Commission Approves Zoledronic acid for the Treatment of Paget's Disease of Bone


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us